Efficacy and safety of sunitinib in patients with
imatinib-resistant or-intolerant gastrointestinal
stromal tumors

Hyo-Jung Leeo, Jae-Yeon Kim, Young-Cheon Song
Department of Pharmacy, Asan Medical Center

[Background]
To assess the efficacy and safety of sunitinib in patients with imatinib-resistant or –intolerant
gastrointestinal stromal tumors(GISTs).

[Methods]
  A retrospective review of the medical records of patients seen between November 2005 and May 2009. Clinical data were collected from 20 consecutive patients with recurrent or metastatic GISTs treated with sunitinib at Asan Medical Center.

[Results]
  The median progression-free survival(FPS) and overall survival(OS) times were 6.5 months and 16.5 months, respectively. The most common grade 3/4 adverse events included thrombocytopenia (40%), neutropenia (20%), anemia (10%), fatigue (20%), stomatitis (15%), hand-foot skin reaction (10%).

[Conclusion]
  Sunitinib was effective and well tolerated in patients with imatinib-resistant or -intolerant GISTs.
 
주제어 : sunitinib, GIST